financetom
Business
financetom
/
Business
/
Organon Shares Rise After Q3 Revenue Beat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Organon Shares Rise After Q3 Revenue Beat
Oct 31, 2024 6:21 PM

10:35 AM EDT, 10/31/2024 (MT Newswires) -- Organon (OGN) shares were advancing nearly 1% in recent Thursday trading after the company posted its Q3 revenue ahead of consensus.

The company reported Q3 non-GAAP net income Thursday of $0.87 per diluted share, unchanged from a year earlier.

Analysts polled by Capital IQ expected $0.90.

Revenue for the quarter ended Sept. 30 rose to $1.58 billion from $1.52 billion a year earlier.

Analysts expected $1.56 billion.

For 2024, the women's health company is projecting revenue of $6.38 billion from $6.43 billion compared with its prior forecast range of $6.25 billion to $6.45 billion.

Analysts are looking for $6.39 billion.

Organon said its board declared a quarterly dividend of $0.28, payable Dec. 12 to stockholders of record on Nov. 12.

As of Sept. 30, Organon had cash and cash equivalents of $763 million.

Price: 18.10, Change: +0.17, Percent Change: +0.95

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Soccer-Huerzeler proud of Brighton's late heroics in victory over Manchester United
Soccer-Huerzeler proud of Brighton's late heroics in victory over Manchester United
Aug 29, 2024
BRIGHTON, England, Aug 24 (Reuters) - Brighton & Hove Albion's new manager Fabian Huerzeler said he was proud of his team's never-say-die display after they beat Manchester United ( MANU ) 2-1 on Saturday with a winning goal in stoppage time. Brighton came into their first Premier League home game of the season as the table toppers and almost found...
US FDA classifies recall of Inari's catheter devices as 'most serious'
US FDA classifies recall of Inari's catheter devices as 'most serious'
Aug 29, 2024
Aug 23 (Reuters) - The U.S. Food and Drug Administration on Friday classified a recall of Inari Medical's ( NARI ) ClotTriever catheter that helps capture and remove large clot from big vessels as most serious. The affected products include all devices and lot numbers with labeled dates prior to Aug. 1, 2024, whose use might cause serious adverse health...
China regulates bond market based on market principles, state media says
China regulates bond market based on market principles, state media says
Aug 29, 2024
SHANGHAI (Reuters) - China's financial regulators approach bond market oversight based on market principles and from macro-prudential and compliance perspectives, state media on Saturday, rejecting claims of market intervention. Chinese authorities in recent weeks halted a long, frenzied rally in the world's second-largest bond market and squelched trading volume with repeated warnings about the risks of reckless buying. Early this...
Eli Lilly Alzheimer's drug to be blocked for use by NHS, The Telegraph reports
Eli Lilly Alzheimer's drug to be blocked for use by NHS, The Telegraph reports
Aug 29, 2024
(Reuters) -Eli Lilly's treatment for early Alzheimer's is expected to be blocked for use by Britain's National Health Service (NHS), the Telegraph reported on Friday. The drug donanemab would be rejected by the National Institute for Health and Care Excellence(NICE), which decides what drugs are available on the NHS, the newspaper reported citing insiders. The NHS, Eli Lilly and NICE...
Copyright 2023-2026 - www.financetom.com All Rights Reserved